Provectus Pharmaceuticals, Inc - PVCT - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 19, 2013

Provectus Pharmaceuticals, Inc - SIC # 2834

Ticker	Exchange	SIC #	Website	Latest Ticker
PVCT	Over the counter	2834	http://www.pvct.com	0.698 +0.078
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Provectus Pharmaceuticals, Inc PROVECTUS PHARMACEUTICALS INC Financials - May 17th, 2013 11:04 am Provectus Updates Shareholders in Its Annual CEO Letter - May 13th, 2013 4:00 am PROVECTUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report - May 9th, 2013 9:04 pm PROVECTUS PHARMACEUTICALS INC Files SEC form 8-K, Unregistered Sale of Equity Securities - Apr 18th, 2013 8:22 am PV-10 Data Presented by Moffitt Cancer Center Researchers Examines Induction of Systemic Immune Response in Multiple Tumor Types - Apr 10th, 2013 11:30 am Current Status of Injectible Therapy - Apr 10th, 2013 10:11 am Provectus Presents Data on PV-10 Combination Therapy at American Association of Cancer Research Annual Meeting - Apr 10th, 2013 10:00 am PV-10 Immunology Data Presented by Moffit Cancer Center Researchers at the American Association for Cancer Research Annual Meeting - Apr 8th, 2013 11:00 am BUYINS.NET Issues Provectus Pharmaceuticals SqueezeTrigger Report - Apr 1st, 2013 6:30 am Immunology Data on PV-10 to Be Presented at the American Association for Cancer Research Annual Meeting - Mar 21st, 2013 4:07 am Data on Provectus's PV-10 to Be Presented at the HemOnc Today – Melanoma and Cutaneous Malignancies Conference on March 22, 2013 - Mar 20th, 2013 4:07 am PROVECTUS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report - Mar 14th, 2013 2:02 pm PROVECTUS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Eq - Feb 28th, 2013 3:21 pm Back to Phase 1: Understanding Systemic Effects of PV-10 - Feb 28th, 2013 7:58 am Provectus Pharmaceuticals Shares Are Trading on the OTCQB - Jan 25th, 2013 5:15 am Provectus Pharmaceuticals Launches Free Mobile Investor Relations Application - Jan 24th, 2013 4:45 am Provectus Pharmaceuticals to Present Data on PV-10 at the American Association for Cancer Research Annual Meeting in April 2013 - Jan 23rd, 2013 5:01 am Presentation Slides From Noble Financial Equity Conference Now Available - Jan 22nd, 2013 6:47 am Provectus Pharmaceuticals Announces H. Lee Moffitt Cancer Center Initiates Phase 1 Study of PV-10 to Elucidate Bystander Effect - Jan 8th, 2013 4:15 am Repurposed diagnostic agent nears phase 3 trials as a treatment for melanoma - Nov 27th, 2012 7:03 am View All Current Headlines >>